Pharmaron Beijing (Stock Code: 03759) Releases January 2026 Share Capital Update

Bulletin Express02-04 16:45

Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January 2026. The company’s authorized share capital for H shares rose from 301,537,125 to 359,977,887, while its A shares advanced from 1,476,658,400 to 1,477,305,741. By the end of January, the total authorized capital amounted to RMB 1,837,283,628.

In respect of H shares, an additional 58,440,762 new shares were issued on January 22, 2026, pursuant to a placing agreement dated January 14, 2026, bringing the total issued H shares (excluding treasury shares) to 352,714,587. Meanwhile, 7,263,300 H shares remain designated as treasury shares for the 2025 H Share Award and Trust Scheme. On the A-share front, 647,341 new shares were issued on January 28, 2026, under 2021 and 2022 Restricted A Share Incentive Schemes, raising the total issued A shares to 1,477,305,741. The company confirmed that its publicly traded shares continue to meet the applicable public float requirement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129099804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129099804","market":"us","top_or_hot":-1,"title":"Pharmaron Beijing (Stock Code: 03759) Releases January 2026 Share Capital Update","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January 2026. The company’s authorized share capital for H shares rose from 301,537,125 to 359,977,887, while its A shares advanced from 1,476,658,400 to 1,477,305,741. By the end of January, the total authorized capital amounted to RMB 1,837,283,628.</p>\n<p>In respect of H shares, an additional 58,440,762 new shares were issued on January 22, 2026, pursuant to a placing agreement dated January 14, 2026, bringing the total issued H shares (excluding treasury shares) to 352,714,587. Meanwhile, 7,263,300 H shares remain designated as treasury shares for the 2025 H Share Award and Trust Scheme. On the A-share front, 647,341 new shares were issued on January 28, 2026, under 2021 and 2022 Restricted A Share Incentive Schemes, raising the total issued A shares to 1,477,305,741. The company confirmed that its publicly traded shares continue to meet the applicable public float requirement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Beijing (Stock Code: 03759) Releases January 2026 Share Capital Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Beijing (Stock Code: 03759) Releases January 2026 Share Capital Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-04 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January 2026. The company’s authorized share capital for H shares rose from 301,537,125 to 359,977,887, while its A shares advanced from 1,476,658,400 to 1,477,305,741. By the end of January, the total authorized capital amounted to RMB 1,837,283,628.</p>\n<p>In respect of H shares, an additional 58,440,762 new shares were issued on January 22, 2026, pursuant to a placing agreement dated January 14, 2026, bringing the total issued H shares (excluding treasury shares) to 352,714,587. Meanwhile, 7,263,300 H shares remain designated as treasury shares for the 2025 H Share Award and Trust Scheme. On the A-share front, 647,341 new shares were issued on January 28, 2026, under 2021 and 2022 Restricted A Share Incentive Schemes, raising the total issued A shares to 1,477,305,741. The company confirmed that its publicly traded shares continue to meet the applicable public float requirement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1129099804","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129099804","pubTimestamp":1770194716,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成（股份代号：03759）发布2026年1月股本更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. (Stock code: 03759) reported an increase in both its H shares listed on the Hong Kong Stock Exchange and its A shares listed on the Shenzhen Stock Exchange for January 2026. The company’s authorized share capital for H shares rose from 301,537,125 to 359,977,887, while its A shares advanced from 1,476,658,400 to 1,477,305,741. By the end of January, the total authorized capital amounted to RMB 1,837,283,628.\nIn respect of H shares, an additional 58,440,762 new shares were issued on January 22, 2026, pursuant to a placing agreement dated January 14, 2026, bringing the total issued H shares (excluding treasury shares) to 352,714,587. Meanwhile, 7,263,300 H shares remain designated as treasury shares for the 2025 H Share Award and Trust Scheme. On the A-share front, 647,341 new shares were issued on January 28, 2026, under 2021 and 2022 Restricted A Share Incentive Schemes, raising the total issued A shares to 1,477,305,741. The company confirmed that its publicly traded shares continue to meet the applicable public float requirement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129099804","isCrawlerRequest":true}